IMCR

Peers: IMTX JANX IOVA REPL XNCR SNDX KURA LEGN GERN TCRX

| Held by: IBB SPDW SBIO BBP CANC GWX ONEQ ISCF APIE IBBQ

Index	-
Market Cap	1.66B
Enterprise Value	1.22B
Income	-18.05M
Sales	430.01M
Book/sh	8.11
Cash/sh	17.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	524
IPO	Feb 05, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	3.87
P/B	3.98
P/C	1.89
P/FCF	-
EV/EBITDA	-
EV/Sales	2.83
Quick Ratio	4.44
Current Ratio	4.47
Debt/Eq	1.04
LT Debt/Eq	1.03
Option/Short	Yes / Yes

EPS (ttm)	-0.35
EPS next Y	-0.60
EPS next Q	-0.13
EPS this Y	90.94%
EPS next Y	-836.93%
EPS next 5Y	65.03%
EPS past 3/5Y	- -
Sales past 3/5Y	31.32% 59.68%
EPS Y/Y TTM	-
Sales Y/Y TTM	20.19%
EPS Q/Q	92.33%
Sales Q/Q	17.10%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-306.19% 5.03%

Insider Own	0.96%
Insider Trans	0.00%
Inst Own	95.61%
Inst Trans	-4.53%
ROA	-1.64%
ROE	-4.47%
ROIC	-2.12%
Gross Margin	98.06%
Oper. Margin	-5.24%
Profit Margin	-4.20%
SMA20	7.64%
SMA50	-1.88%
SMA200	1.47%
Trades

Shs Outstand	51.48M
Shs Float	51.00M
Short Float	15.50%
Short Ratio	18.11
Short Interest	7.90M
52W High	40.71 -20.71%
52W Low	27.50 17.40%
Volatility	5.28% 4.18%
ATR (14)	1.29
RSI (14)	58.79
Beta	0.82
Rel Volume	2.16
Avg Volume	436.32K
Volume	858,398

Perf Week	13.92%
Perf Month	-0.42%
Perf Quarter	-9.08%
Perf Half Y	7.69%
Perf YTD	-6.99%
Perf Year	-3.83%
Perf 3Y	-31.70%
Perf 5Y	-14.46%
Perf 10Y	-
Recom	1.64
Target Price	64.17
Prev Close	32.60
Price	32.28
Change %	-0.97%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-21-26	Resumed	JP Morgan	Overweight	$50
Mar-16-26	Downgrade	Jefferies	Buy → Hold	$33
Jan-07-26	Upgrade	UBS	Sell → Buy	$55
Oct-31-25	Initiated	Wells Fargo	Overweight	$60
Sep-18-25	Resumed	Guggenheim	Neutral
Aug-25-25	Resumed	Jefferies	Buy	$48
May-27-25	Initiated	Deutsche Bank	Buy	$65
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$74 → $35
Nov-11-24	Downgrade	Mizuho	Outperform → Neutral	$72 → $38
Oct-24-24	Initiated	UBS	Sell	$24
Oct-07-24	Downgrade	Guggenheim	Buy → Neutral
Apr-29-24	Initiated	Leerink Partners	Outperform	$74
Nov-20-23	Resumed	JP Morgan	Overweight	$60
Nov-02-23	Initiated	Cantor Fitzgerald	Overweight
Oct-31-23	Initiated	Robert W. Baird	Outperform	$84
Sep-13-23	Upgrade	JP Morgan	Neutral → Overweight	$9 → $22
Sep-13-23	Initiated	Needham	Buy	$75
Aug-16-23	Initiated	CapitalOne	Overweight	$84
Jul-17-23	Initiated	Canaccord Genuity	Hold	$67
Mar-31-23	Initiated	Mizuho	Buy	$70

Show Previous Ratings

Oct-15-26 07:00AM	Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI - its first tissue-specific autoimmune candidate - for patients with type 1 diabetes (GlobeNewswire)
Sep-14-26 07:00AM	Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK (tebentafusp) in previously treated advanced melanoma (GlobeNewswire)
Sep-01-26 07:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
Aug-06-26 03:02PM	Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Kimtrak Growth and Pipeline ... (GuruFocus.com)
01:06PM	Immunocore Holdings PLC (IMCR) (Q2 2026) Earnings Call Highlights: Strong Kimtrak Growth and ... (GuruFocus.com)
07:00AM	Loading…
07:00AM	Immunocore reports second quarter financial results and provides a business update (GlobeNewswire)
Jul-30-26 07:00AM	Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (GlobeNewswire)
May-31-26 08:00AM	Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma (GlobeNewswire)
May-06-26 07:00AM	Immunocore reports first quarter financial results and provides a business update (GlobeNewswire) +6.55%
Apr-19-26 06:00PM	KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma (GlobeNewswire)
Apr-06-26 07:00AM	Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-26 04:30PM	Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (GlobeNewswire)
Mar-16-26 09:37AM	Qualcomm, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Mar-05-26 09:00AM	Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types (PR Newswire) -5.34%
Mar-03-26 07:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
02:21PM	Loading…
Feb-25-26 02:21PM	Immunocore Q4 Earnings Call Highlights (MarketBeat)
02:01PM	Immunocore Holdings PLC (IMCR) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
10:56AM	JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations (Zacks)
10:21AM	RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up (Zacks)
09:10AM	Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
08:55AM	Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y (Zacks)
07:00AM	Immunocore reports fourth quarter and full year 2025 financial results and provides a business update (GlobeNewswire)
Feb-20-26 09:59AM	Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down (Zacks)
Feb-18-26 07:00AM	Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (GlobeNewswire)
Feb-17-26 12:00PM	Immunocore (IMCR) Upgraded to Strong Buy: Here's Why (Zacks)
Feb-13-26 12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
Feb-06-26 11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
Feb-05-26 10:49AM	Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-04-26 09:16AM	NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View (Zacks)
Feb-03-26 10:43AM	NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study (Zacks)
07:52AM	Loading…
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
Jan-30-26 09:47AM	Immunocore Holdings (IMCR) is One of the Best Small Cap Stocks Ready to Explode in 2026 (Insider Monkey)
07:00AM	Immunocore announces R&D leadership evolution (GlobeNewswire)
Jan-29-26 11:23AM	TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth (Zacks)
Jan-27-26 02:07PM	BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down (Zacks)
Jan-23-26 11:13AM	CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study (Zacks)
Jan-22-26 11:39AM	MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data (Zacks)
07:10AM	Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Jan-21-26 10:31AM	FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate (Zacks) +5.88%
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-09-26 07:00AM	Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-26 12:00PM	Immunocore (IMCR) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Dec-09-25 12:20AM	Immunocore Holdings plc (IMCR) Asserts Pipeline Development and Strong Commercial Performance (Insider Monkey)
Nov-10-25 07:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
Nov-07-25 08:00AM	Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting (GlobeNewswire) +6.03%
Nov-06-25 10:00AM	Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:00AM	Immunocore reports third quarter financial results and provides a business update (GlobeNewswire)
Nov-03-25 11:19AM	Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-31-25 09:33AM	Apple upgraded, Comcast downgraded: Wall Street's top analyst calls (The Fly)
Oct-27-25 06:42PM	Growth Picks: 3 Low-Cost Stocks That Could Double in Value (MarketBeat)
Oct-20-25 11:08PM	H.C. Wainwright Remains Bullish on Immunocore Holdings plc (IMCR) (Insider Monkey)
Sep-04-25 07:00AM	Immunocore to present at upcoming investor conferences (GlobeNewswire)
Aug-08-25 12:47PM	IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi (Zacks)
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
11:19AM	Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus (Zacks)
11:01AM	Immunocore Holdings PLC (IMCR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
10:26AM	PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues (Zacks)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks)
11:00AM	Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates (Zacks)
10:08AM	Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:04AM	Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
09:30AM	Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics (Zacks)
08:17AM	ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum (Zacks)
07:00AM	Immunocore reports second quarter financial results and provides a business update (GlobeNewswire)
Aug-06-25 12:16PM	Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles (Zacks)
11:57AM	HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks)
11:51AM	BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark (Zacks)
11:48AM	RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down (Zacks)
11:43AM	Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
11:42AM	ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
11:07AM	Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut (Zacks)
09:22AM	JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut (Zacks)
Aug-05-25 12:21PM	ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised (Zacks)
12:12PM	TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line (Zacks)
11:54AM	CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption (Zacks)
11:36AM	AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
11:33AM	VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal (Zacks)
10:17AM	BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View (Zacks)
08:59AM	KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook (Zacks)
Aug-01-25 12:04PM	CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down (Zacks)
11:49AM	FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
Jul-31-25 10:37AM	Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
10:15AM	UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y (Zacks)
02:00AM	Immunocore to report second quarter 2025 financial results and host call on August 7, 2025 (GlobeNewswire)
Jul-30-25 10:23AM	Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales (Zacks)
Jul-24-25 09:55AM	Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High? (Zacks)
Jul-08-25 10:54AM	COGT Stock Soars on Phase III Systemic Mastocytosis Study Success (Zacks)
10:38AM	MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy (Zacks)
Jul-03-25 10:32AM	Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study (Zacks)
Jul-02-25 10:32AM	Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli (Zacks)
09:28AM	5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment (Zacks)
Jul-01-25 10:50AM	Biogen Begins Phase III Felzartamab Study for Third Kidney Disease (Zacks)
Jun-30-25 11:40AM	RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome (Zacks)
08:00AM	Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions (GlobeNewswire)
Jun-25-25 11:17AM	KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study (Zacks)
11:14AM	Strength Seen in Kamada (KMDA): Can Its 9.5% Jump Turn into More Strength? (Zacks)
11:06AM	Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU (Zacks)
10:02AM	Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag (Zacks)
Jun-24-25 11:58AM	CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
David Berman	Affiliate	May 22 '26	Proposed Sale	29.48	69,271	2,042,148		May 22 03:44 PM
David Berman	Affiliate	May 21 '26	Proposed Sale	29.15	65,000	1,894,638		May 21 01:56 PM
David Berman	Affiliate	Apr 08 '26	Proposed Sale	31.85	25,000	796,250		Apr 08 03:57 PM
David Berman	affiliate	Mar 11 '26	Proposed Sale	32.57	11,832	385,330		Mar 11 01:47 PM
Jallal Bahija	CHIEF EXECUTIVE OFFICER	Feb 17 '26	Option Exercise	0.00	23,817	0	23,817	Feb 19 05:00 PM
Jallal Bahija	CHIEF EXECUTIVE OFFICER	Feb 18 '26	Sale	32.35	11,474	371,184	12,343	Feb 19 05:00 PM
GOLL JOHN	SVP, FINANCE & CAO	Feb 17 '26	Option Exercise	0.00	1,351	0	1,351	Feb 19 05:00 PM
GOLL JOHN	SVP, FINANCE & CAO	Feb 18 '26	Sale	32.35	698	22,580	653	Feb 19 05:00 PM
St Leger Tina Amber	CHIEF HR OFFICER	Feb 17 '26	Option Exercise	0.00	2,119	0	2,119	Feb 19 05:00 PM
St Leger Tina Amber	CHIEF HR OFFICER	Feb 18 '26	Sale	32.35	1,000	32,350	1,119	Feb 19 05:00 PM
Berman David M	HEAD OF R&D	Feb 17 '26	Option Exercise	0.00	11,824	0	11,824	Feb 19 05:00 PM
Berman David M	HEAD OF R&D	Feb 18 '26	Sale	32.35	5,965	192,968	5,859	Feb 19 05:00 PM
David Berman	affiliate	Feb 18 '26	Proposed Sale	32.35	5,965	192,951		Feb 18 04:22 PM
Tina St Leger	affiliate	Feb 18 '26	Proposed Sale	32.35	1,000	32,347		Feb 18 04:19 PM
Bahija Jallal	affiliate	Feb 18 '26	Proposed Sale	32.35	11,474	371,152		Feb 18 04:18 PM
Berman David M	HEAD OF R&D	Dec 04 '25	Option Exercise	17.46	31,341	547,214	31,341	Dec 08 04:15 PM
Berman David M	HEAD OF R&D	Dec 05 '25	Option Exercise	17.46	572	9,987	572	Dec 08 04:15 PM
Berman David M	HEAD OF R&D	Dec 04 '25	Sale	40.26	31,341	1,261,789	0	Dec 08 04:15 PM
Berman David M	HEAD OF R&D	Dec 05 '25	Sale	40.14	572	22,960	0	Dec 08 04:15 PM
Berman David M	HEAD OF R&D	Nov 26 '25	Option Exercise	17.46	69,404	1,211,794	69,404	Dec 01 04:10 PM
Berman David M	HEAD OF R&D	Nov 28 '25	Option Exercise	17.46	5,521	96,397	5,521	Dec 01 04:10 PM
Berman David M	HEAD OF R&D	Nov 26 '25	Sale	40.12	69,404	2,784,488	0	Dec 01 04:10 PM
Berman David M	HEAD OF R&D	Nov 28 '25	Sale	40.09	5,521	221,337	0	Dec 01 04:10 PM
Berman David M	HEAD OF R&D	Nov 25 '25	Option Exercise	17.46	18,020	314,629	18,020	Nov 26 04:10 PM
Berman David M	HEAD OF R&D	Nov 24 '25	Option Exercise	17.46	100	1,746	100	Nov 26 04:10 PM
Berman David M	HEAD OF R&D	Nov 25 '25	Sale	40.03	18,020	721,341	0	Nov 26 04:10 PM
Berman David M	HEAD OF R&D	Nov 24 '25	Sale	40.00	100	4,000	0	Nov 26 04:10 PM
David M. Berman	Officer	Nov 24 '25	Proposed Sale	39.35	136,790	5,382,687		Nov 24 04:56 PM

Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease. the firm's lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

CEO & Executive DirectorDr. Bahija Jallal Ph.D.

CFOMr. Travis Alan Coy M.B.A.

Executive VP & Chief Operating OfficerDr. Kripa Ram Ph.D.

SVPMr. John Goll III

Chief Science and Technology Officer & Milton Park Site HeadMs. Annelise Vuidepot Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Immunocore Holdings plc ADR

Upgrade your Finviz experience